Quantitative analysis of in vitro systems of B cell activation and plasma cell differentiation can be used to estimate parameters of B cell behavior necessary for immune responses, and to suggest strategies for manipulation of B cell immune responses. Antibody mediated rejection of kidney transplants involves activation of B cells, which produce plasma cells that secrete antibodies against cell surface markers present in the transplant. While a variety of therapeutic agents can affect B cell proliferation, death, and differentiation, we currently lack robust quantitative models to guide the design of clinical trials. The overall goal of this work is to develop such a framework.
Our first aim i s to develop and experimentally validate a multi-type Bellman- Harris branching process of B cell proliferation and terminal plasma cell differentiation. Current models of B cell differentiation are either continuous population based ordinary differential equation (ODE) models or non-quantitative graphical representations of experimental observations. We propose an alternative approach, a multi-type branching stochastic process coupled with discrete event, agent based modeling of individual virtual B cells in silico. Model parameters will be estimated and the model validated with new statistical methods described in Aim 2 using data from a novel in vitro plasma cell differentiation system we have developed.
Our second aim i s to develop and experimentally validate rigorous statistical methods for lymphocyte kinetic parameter estimation from CFSE labeling experiments. We will develop novel statistical methods (estimation, test, goodness-of-fit) for the quantitative analysis of CFSE data. In contrast to currently available approaches, the proposed methods will make it feasible to estimate parameters of cell activation, proliferation, differentiation and death. We will study their theoretical properties (such as consistency and asymptotic normality of estimators), provide expressions for the variance-covariance matrix of the proposed estimators, and evaluate their finite sample performance in extensive simulation studies.
Our third aim i s o model the effects of agents that impede the GO->G1 progression (sirolimus), delay S/M transition (mycophenolate mofetil), or prevent cell cycle exit (IL-6 antagonists) on plasma cell generation and perform in vitro model validation. We will use a novel in vitro culture system to drive human B cells from activation to terminal plasma cell differentiation. Using the techniques developed in Aim 2, we will estimate kinetic parameters for each B cell class during differentiation in the presence of sirolimus, mycophenolate mofetil, and IL-6 blocking antibodies. The stochastic branching process model developed in Aim 1 will be used to predict experimental outcomes and compare them with in vitro data. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI069351-01A2
Application #
7313569
Study Section
Modeling and Analysis of Biological Systems Study Section (MABS)
Program Officer
Gondre-Lewis, Timothy A
Project Start
2007-05-15
Project End
2011-04-30
Budget Start
2007-05-15
Budget End
2008-04-30
Support Year
1
Fiscal Year
2007
Total Cost
$333,540
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Rosenberg, Alexander; Fucile, Christopher; White, Robert J et al. (2018) Visualizing nationwide variation in medicare Part D prescribing patterns. BMC Med Inform Decis Mak 18:103
Nogales, Aitor; Piepenbrink, Michael S; Wang, Jiong et al. (2018) A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. Sci Rep 8:4374
Clark, Amelia M; DeDiego, Marta L; Anderson, Christopher S et al. (2017) Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins. PLoS One 12:e0188267
Huang, Junqiong; Hilchey, Shannon P; Wang, Jiong et al. (2017) IL-15 enhances cross-reactive antibody recall responses to seasonal H3 influenza viruses in vitro. F1000Res 6:2015
Li, Dongmei; Xie, Zidian; Zand, Martin et al. (2017) Bon-EV: an improved multiple testing procedure for controlling false discovery rates. BMC Bioinformatics 18:1
Yang, Hongmei; Baker, Steven F; González, Mario E et al. (2016) An improved method for estimating antibody titers in microneutralization assay using green fluorescent protein. J Biopharm Stat 26:409-20
Hyrien, Ollivier; Baran, Andrea (2016) Fast Nonparametric Density-Based Clustering of Large Data Sets Using a Stochastic Approximation Mean-Shift Algorithm. J Comput Graph Stat 25:899-916
Sandal, Shaifali; Zand, Martin S (2015) Rational clinical trial design for antibody mediated renal allograft injury. Front Biosci (Landmark Ed) 20:743-62
Wang, Jiong; Hilchey, Shannon P; Hyrien, Ollivier et al. (2015) Multi-Dimensional Measurement of Antibody-Mediated Heterosubtypic Immunity to Influenza. PLoS One 10:e0129858
Qiu, Xing; Wu, Shuang; Hilchey, Shannon P et al. (2015) Diversity in Compartmental Dynamics of Gene Regulatory Networks: The Immune Response in Primary Influenza A Infection in Mice. PLoS One 10:e0138110

Showing the most recent 10 out of 31 publications